Alnylam Pharmaceuticals, Inc. vs ProShares Bitcoin ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.04 (market cap $29.60B), while ProShares Bitcoin ETF trades at $8.56. Which is the better fit depends on your goals.
| ALNY | BITO | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Crypto-linked |
52-Week High | $491.22 | $22.27 |
52-Week Low | $205.48 | $7.98 |
Enterprise Value | $27.56B | — |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
BITO trades at $8.64 with no recent price movement, showing technical bearish signals from moving averages while oscillators remain neutral. The ETF faces headwinds as recent analysis highlights underperformance compared to spot Bitcoin ETFs, with Seeking Alpha maintaining a Sell rating for retail investors. Dividend distributions of $0.01 per share provide modest income but haven't offset significant price declines over the past year.
The outlook remains challenging with institutional sentiment turning cautious amid crypto market volatility. Key risks include high fee structures, competitive pressure from newer spot Bitcoin ETFs, and correlation breakdowns with traditional risk assets. Analyst consensus leans bearish given the fund's structural disadvantages and ongoing crypto winter conditions.
Trailing returns across standard periods
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →